LAKESHORE BIOP.DL-,000005 Aktie

The buyer group led by Oceanpine Capital has declared its intention to withdraw from the privatization of LakeShore Biopharma agreed in November 2025 (USD 0.90 per share), citing arbitration awards that impose a liability of around 576,500,000 RMB (about USD 82 million) and thus represent a “material adverse effect.” The stock subsequently plunged to USD 0.40, a decline of more than 50% for the week. The extraordinary general meeting originally scheduled for February 12 was postponed; the buyer consortium signals willingness to negotiate amended deal terms. LakeShore will review the claims and disclose further information as required by law. » More on de.investing.com

The independent special committee of LakeShore Biopharma has engaged financial and legal advisers (Kroll, Gibson Dunn & Crutcher, Maples and Calder) to review a non-binding takeover proposal received on Aug. 26. No deal has been guaranteed; the announcement lacked details on bidders and terms. At the same time, the company received an offer from Oceanpine Capital of $0.86 per share and secured a $15 million private placement that includes the issuance of common stock and warrants. » More on de.investing.com